AB027. Clinical analysis of transurethral vaporesection of the prostate using the 2-micron continuous wave laser for the treatment of benign prostatic hyperplasia

The present study aimed to evaluate the effects of transurethral dividing vaporesection of the prostate in the management of benign prostatic hyperplasia (BPH). From October 2006 to June 2012, a total of 377 patients who met the inclusion criteria with low urinary tract symptom secondary to BPH were treated transurethrally under epidural or sacral anesthesia using the dividing vaporesection technique. Of these 203 had a prostate volume of ≤80 mL and 174 had a prostate volume of >80 mL. Pre- and post-operative data were evaluated for prostate-specific antigen (PSAs, post-void residual volume (PVR), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS) and quality of life (QoL). Out of the 377 cases, 369 cases were followed up to 5 years finally. All the surgical procedures were successfully conducted under epidural or general anesthesia. Mean operation time was 79±21 minutes, and mean retrieved prostatic tissue was 22.7±5.6 g. Resected prostatic tissues could be easily flashed out of the bladder. There were no significant differences in serum sodium concentrations and hemoglobin levels before and after the surgery. Mean catheter time and hospital stay was 121±47 hours and 5.5±2.0 days respectively. During follow up, Qmax increased from 8.1±3.7 mL/s preoperatively to 4.5±3.9 mL/s by the end of the follow up (P<0.05), IPSS and QoL-Score improved from 23.6±4.7 and 3.8±0.9 to 5.7±2.6 and 1.6±1.2 respectively (P<0.05), and PVR decreased from 244±73 to 28±22 mL. The data indicated that transurethral vaporesection of prostate using the 2-micron continuous wave laser system is a safe and effective treatment for BPH.